Literature DB >> 30985924

A Case of Reversible Cerebral Vasoconstriction Syndrome Triggered by High-Dose Methotrexate in a Boy With Lymphoma.

Xiaona Wang1, Yan Zhang2, Hui You3, Tienan Zhu2, Daobin Zhou2.   

Abstract

BACKGROUND: Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by thunderclap headaches and transient segmental cerebral arterial vasoconstriction. Many drugs have been identified as triggers of RCVS. However, RCVS induced by methotrexate (MTX), an antimetabolite agent, has never been reported. CASE: We report the first case of a 17-year-old Chinese student with a thunderclap headache after administration of high-dose methotrexate during the treatment of extranodal natural killer/T-cell lymphoma. Brain magnetic resonance angiography showed segmental constriction of the right anterior cerebral artery A1 segment, combined with nonaneurysmal cortical subarachnoid hemorrhage and vasogenic brain edema in brain magnetic resonance imaging. Cerebral images became normal 6 weeks later. DISCUSSION: MTX is associated with a variety of neurological toxicities, including aseptic meningitis, transverse myelopathy, acute and subacute encephalopathy, and leukoencephalopathy. However, this is the first report that MTX can trigger RCVS, although it is not a proof for causality. RCVS should be a differential diagnosis for a headache after MTX administration.
© 2019 American Headache Society.

Entities:  

Keywords:  high-dose methotrexate; reversible cerebral vasoconstriction syndrome; thunderclap headache

Year:  2019        PMID: 30985924     DOI: 10.1111/head.13526

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  2 in total

1.  Effects of oxiracetam combined with ginkgo biloba extract in the treatment of acute intracerebral hemorrhage: A clinical study.

Authors:  Xiu-Xiu Li; Shi-Hui Liu; Su-Jing Zhuang; Shi-Feng Guo; Shou-Liang Pang
Journal:  Brain Behav       Date:  2020-06-12       Impact factor: 2.708

2.  Reversible cerebral vasoconstriction syndrome after intrathecal cytarabine.

Authors:  Natalia Trombini Mendes; Luiza Ramos de Freitas; Rônney Pinto Lopes; Lohana Santana Almeida da Silva; Francisco Tomaz Meneses de Oliveira
Journal:  Hematol Transfus Cell Ther       Date:  2020-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.